JPS60176595A - Preparation of physiologically active substance ml-236a and monacolin j - Google Patents

Preparation of physiologically active substance ml-236a and monacolin j

Info

Publication number
JPS60176595A
JPS60176595A JP3113784A JP3113784A JPS60176595A JP S60176595 A JPS60176595 A JP S60176595A JP 3113784 A JP3113784 A JP 3113784A JP 3113784 A JP3113784 A JP 3113784A JP S60176595 A JPS60176595 A JP S60176595A
Authority
JP
Japan
Prior art keywords
monacolin
active substance
physiologically active
producing
genus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3113784A
Other languages
Japanese (ja)
Inventor
Akira Endo
遠藤 章
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP3113784A priority Critical patent/JPS60176595A/en
Publication of JPS60176595A publication Critical patent/JPS60176595A/en
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

PURPOSE:To prepare a physiologically active substance ML-236A from ML-236B or monacolin J from monacolin K, by using a microorganism belonging to the genus Mortierella, etc. CONSTITUTION:Live or dead microbial cells of a microorganism belonging to the genus Mortierella, Emericella, Diheterospora, Himicola, etc., e.g. Mortierella isabellina IFO7884 or Emericella unguis IFO8087, or an enzyme extracted from the above-mentioned microorganism is brought into contact with a substance ML-236B or monacolin K.

Description

【発明の詳細な説明】 本発明は生理活性物質ML〜236人及び七ナコリンJ
の新規な製造法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides physiologically active substances ML-236 and Nanacolin J.
Concerning a new manufacturing method.

ML −236A及びモナコリンJはさきに本発明者ら
Kよってペニシリウム属及びモナスカス属に属するかび
の培養物中から発見された公知の物質で次の構造<1)
を有する。
ML-236A and Monacolin J are known substances previously discovered by the present inventors in the culture of molds belonging to the genus Penicillium and Monascus, and have the following structure <1)
has.

(1) ML−236A(R=H) モナコリンJ(R=CH,) 又ML −236B及びモナコリンにも本発明者らによ
り夫々ペニシリウム属及びモナスカス属から発見された
公知の物質で以下の構造を有する(特開昭50−155
690号及び特開昭55−111790号)。
(1) ML-236A (R=H) Monacolin J (R=CH,) ML-236B and Monacolin are also known substances discovered by the present inventors from the genus Penicillium and the genus Monascus, respectively, and have the following structures. (Unexamined Japanese Patent Publication No. 50-155
No. 690 and JP-A-55-111790).

@ ML−236B(R=H) モナコリンK (R=CH,) ML−236A 、 ML−236B 、七ナコリンJ
及びモナコリンにはコレステμm用生合成を強(阻害し
、動物の血中コレステルール低下作用を有する。
@ ML-236B (R=H) Monacolin K (R=CH,) ML-236A, ML-236B, Sevennacolin J
Monacolin strongly inhibits the biosynthesis of cholesterol μm and has the effect of lowering blood cholesterol in animals.

ML −236B及びモナコリンにはアルカリ処理によ
り夫々ML −236A及びモナコリンJに変換するこ
とができるが、その収率は通常50−以下である。
ML-236B and monacolin can be converted to ML-236A and monacolin J, respectively, by alkali treatment, but the yield is usually 50- or less.

ML−236A及びモナフリンJはそれ自身も血中−レ
ステμmル低下作用を有するが、更に活性の優れた各種
誘導体を合成するための貴重な原料でもある。
ML-236A and Monafrin J themselves have a blood level μm-lowering effect, but they are also valuable raw materials for synthesizing various derivatives with even better activity.

本発明者は微生物により大量製造が可能な凧−236B
及び七ナコリンKを夫々ML −236A及びモナコリ
ンJK変換することについて広く研究を進めたところ、
特定の微生物によりほぼ100%の変換率でML −2
36B及びモナコリンKを夫々ML −236A及びモ
ナコリンJに変換できることを見出し、本発明を完成し
た。
The present inventor has developed a kite-236B that can be manufactured in large quantities using microorganisms.
We conducted extensive research on converting 7 nacolin K to ML-236A and monacolin JK, respectively.
ML-2 with almost 100% conversion rate by specific microorganisms
The present invention was completed by discovering that 36B and monacolin K can be converted into ML-236A and monacolin J, respectively.

従って、本発明は優れた特性を有するML −236A
及びモナコリンJの新規な製造法を提供するものである
Therefore, the present invention provides ML-236A with excellent characteristics.
and a novel method for producing Monacolin J.

ML −236B及び七ナコリンKを夫々ML−236
A及びモナコリンJに変換する微生物としてはモルチレ
ラ属、エメリセラ属、ジヘテロスポラ属。
ML-236B and Hepnacolin K respectively in ML-236
Microorganisms that convert into A and Monacolin J include Mortillera, Emericella, and Diheterospora.

フミコラ属、ジコトモミセス属、ネオコスモスボラ属、
キシルボン属、トルpiセス属、及びチェラビア属に属
するかびがあげられる。これらに属するかびの中で特に
、モルチレラ拳イサベリナrF07884 (Mort
lerella l5aballlna ) r zメ
リセラ・ラングイスIFO8087(Eh+erice
lla ungulg ) 、ジヘテロスポラ・クラミ
ドスポリアIFO9249(Dlheterospor
achlamydosporla ) + フミコラ・
7スコアトラ IFO9530(、Humlcola 
fuacoatra ) +ジ3トモミセス0セジュピ
IFO9929(Dlchotomomyc*a ce
Jp目)Iネオ7スモスポラ・アフリカナIFO759
0(Neocoa+nosporaafrlean& 
) +キシルボン・スフzpスポラIFO9516(X
ylogone gphaeroapora )’ 、
 )ルーミセス・ラグナIFO30008、チェラビア
・ヒメテイIFO30419(Th1elavla f
lmetl )が好適である。これらの微生物はすべて
公的な菌保存機関(IFO又はNRRL )より入手可
能である。
Humicola spp., Dichotomomyces spp., Neocosmosvora spp.
Examples include molds belonging to the genus Xylbone, genus Torpices, and genus Cherabia. Among these molds, Mortillera fistula Isabelina rF07884 (Mort.
lerella l5aballna) r z Mericela Languis IFO8087 (Eh+erice
lla ungulg), Diheterospora chlamydosporia IFO9249 (Dlheterospora
achlamydosporla) + Humicola・
7 score tiger IFO9530 (, Humlcola
fuacoatra) + Di3 Tomomyces 0 Sejupi IFO9929
Jp) I Neo 7 Smospora africana IFO759
0 (Neocoa + nospora afrlean &
) +Xilbon Sufzp Spora IFO9516 (X
ylogone gphaeroapora)',
) Rumises laguna IFO30008, Chelavia himetei IFO30419 (Th1elavla f
lmetl ) is preferred. All of these microorganisms are available from public microorganism repositories (IFO or NRRL).

ML −236B及びモナコリンKを夫々ML −23
6A及びモナコリンJに変換するには微生物生菌体はも
ちろん、微生物死菌体(例えばアセトン乾燥菌体)、微
生物から抽出した酵素(例えばエステラーゼ)及び固定
化した菌体及び酵素をML−236B及びモナコリンに
と接触させることによって達成される。この場合、 M
L −236B及びモナコリンにはラクトン環が開裂し
たアルカリ金属塩として使用するのが好ましい。
ML-236B and Monacolin K were added to ML-23, respectively.
To convert to 6A and Monacolin J, not only live microbial cells, but also killed microbial cells (e.g., acetone-dried cells), enzymes extracted from microorganisms (e.g., esterase), and immobilized cells and enzymes are converted into ML-236B and monacolin J. This is achieved by contacting with Monacolin. In this case, M
It is preferable to use L-236B and monacolin as an alkali metal salt with a cleaved lactone ring.

又ML−236A及びモナコリンJは条件により大部分
がラクトン環の開裂したアルカリ金属塩又は遊離酸どし
て生成される。接触の方法は%に制限されないが、20
−40℃で行うのが好ましい。
Depending on the conditions, ML-236A and Monacolin J are mostly produced as alkali metal salts or free acids with cleaved lactone rings. The method of contact is not limited to 20%, but
Preferably it is carried out at -40°C.

斯くして得られる培養液又は反応液から、溶媒抽出、各
種りμマドグラフィー、結晶化操作等により目的物ML
 −236A及びモナコリンJを単離するεとができる
From the culture solution or reaction solution obtained in this way, the target product ML is obtained by solvent extraction, various μmography, crystallization operations, etc.
-236A and monacolin J can be isolated.

次に実施例を示す。Next, examples will be shown.

実施例1 グルツース1チ、ペプトン0.2 % 、肉エキスOl
チ、酵母エキス0.1 % I C8L 0.3 %か
らなる培地100−を含む坂ロフラスコ(2本)Kエメ
リセラ・ラングイスIF08087を接種し25℃で2
日間振とう培養した。その後ML−236BのNa塩(
ラクトン環の開裂したもの)を各フラスコに5(+1n
f加えて更に25℃で20時間振と5を続げた。これK
よりML −236Bの90%以上がML −236A
に変換された。次いで培養ろ液を得てトリフルオル酢酸
でpH3としてから酢酸エチル約300−で凧−236
Aを抽出した。抽出液を脱水乾固したのち乾固物をIO
+dの酢酸エチルに溶がし、5≠l炭酸す)11ウム溶
液lO−で洗浄した。酢酸エチル層を乾固後含水エタノ
ール中で結晶化を行ないML−236A 6ft■を得
た。得られた標品の各種物性(UV吸収+ IRE? 
+ NMRスヘク) ル、−qススベクトル等)は公知
のML −2361,の物性と一致した。
Example 1 1 glutoose, 0.2% peptone, meat extract ol
H. Sakaro flasks (2 bottles) containing 100-ml medium consisting of 0.1% yeast extract and 0.3% IC8L were inoculated with Emelysella languis IF08087 and incubated at 25°C for 2 hours.
Cultured with shaking for 1 day. After that, the Na salt of ML-236B (
(lactone ring cleavage) was added to each flask.
In addition, shaking was continued at 25° C. for 20 hours. This is K
More than 90% of ML-236B is ML-236A.
Converted to . Next, the culture filtrate was obtained, adjusted to pH 3 with trifluoroacetic acid, and then diluted with ethyl acetate of about 300-236 mm.
A was extracted. After dehydrating the extract to dryness, the dried product was IO
The solution was dissolved in +d of ethyl acetate and washed with 11 um solution of 5≠l carbonate. The ethyl acetate layer was dried and then crystallized in aqueous ethanol to obtain ML-236A 6ft. Various physical properties of the obtained standard (UV absorption + IRE?
+NMR spectrum, -q soot vector, etc.) were consistent with the known physical properties of ML-2361.

実施例2 実施例1と同じ条件でエメリセラ・ラングイスIF08
087を生育させ、これにモナコリンにのNa塩を坂ロ
フラスコ2本に夫々50■加えた。以下、実施例1と同
じ操作を進めてモナコリンJの結晶62mgを得た。得
られた標品の各漬物性は公知のモナコリンJのものと一
致した。
Example 2 Emericera languis IF08 under the same conditions as Example 1
087 was grown, and 50 μ of Na salt from monacolin was added to each of two Sakaro flasks. Thereafter, the same operation as in Example 1 was carried out to obtain 62 mg of Monacolin J crystals. The pickle properties of the obtained sample matched those of the known Monacolin J.

実施例3 実施例1と同じ培地を含む坂ロフラスコにモルチレラ・
イサベリナIFO7884、ジヘテμスポラ・タラミド
スポリ7 IFQ 9249 、フミコラ・フスフ7 
) 5 IFO9530、シコトモミセス・セジュピI
FO9929、ネオコスモスボラ・アフリカナIFO7
590゜キシ−ボン・スフエルスポラIFO9516、
)ルーミセス・ラグナrFo 30008及びチェラビ
ア・ヒメテイIF030419を夫々接種して25℃で
3日間振と5培養した(各菌株につき坂ロフラスコ2本
)。
Example 3 In a Sakalo flask containing the same medium as in Example 1, Mortillera.
Isabelina IFO 7884, Jihete μspora thalamidospoli 7 IFQ 9249, Humicola fusuf 7
) 5 IFO9530, Shichotomomyces sedupi I
FO9929, Neocosmos Bora africana IFO7
590゜Xyvon Spheluspora IFO9516,
) Rumyces laguna rFo 30008 and Chelavia himetei IF030419 were each inoculated and cultured at 25° C. for 3 days with shaking (2 Sakaro flasks for each strain).

次いで、夫々の菌株を培養した坂ロフラスコ2本のうち
の一万にはML−236B(ラクトン型) 50■を、
又他の1本にはモナコリンK(ラクトン型)50ツを加
えて更に25℃で2日間振と5培養を続けた。培養終了
後夫々のフラスコの内容物がらろ液を得て、トリフルオ
ル酢酸でpH3とし【から酢酸エチル100m/で抽出
した。抽出液を脱水乾固して得られた乾固物をメタノー
ルに溶解し、日本分光社製為速液体クロマトグラフィ(
シリカODSカラム)Kかげ、生成したML −236
A又はモナコリンKを分取した。坂ロフラスコ1本分か
らの夫々の収量(キ)は表1の如くであった。
Next, 50 μ of ML-236B (lactone type) was added to 10,000 of the two Sakaro flasks in which each strain was cultured.
In addition, 50 monacolin K (lactone type) was added to the other tube, and the culture was continued at 25° C. for 2 days with shaking. After completion of the culture, the contents of each flask were collected to obtain a filtrate, adjusted to pH 3 with trifluoroacetic acid, and extracted with 100 m/ml of ethyl acetate. The extract was dehydrated to dryness, the resulting dry matter was dissolved in methanol, and subjected to a rapid liquid chromatography method (manufactured by JASCO Corporation).
Silica ODS column) K shadow, generated ML-236
A or monacolin K was fractionated. The respective yields (ki) from one Sakaro flask were as shown in Table 1.

実施例4 実施例1と同じ培地を含む坂ロフラスコにエメリセラ・
ラングイスIF08087を接種して25℃で2日間振
と5培養した。ろ過により菌体な寒め、十分脱水した後
−30℃に予め冷却しであるアセトン中に菌体を加えた
。軽く攪拌してからろ過により菌体な集め、更に十分7
セトンで洗浄してから菌体な吸引乾固して7セトン乾燥
菌体を得た。
Example 4 Into a Sakalo flask containing the same medium as in Example 1, Emericella
Languis IF08087 was inoculated and cultured at 25°C for 2 days with shaking. The cells were cooled by filtration, thoroughly dehydrated, and then added to acetone that had been previously cooled to -30°C. After stirring gently, collect the bacterial cells by filtration, and leave for another 70 minutes.
After washing with setone, the cells were vacuum dried to obtain 7 setone-dried cells.

50mMリン酸カリバッフ7− (pH8,0) jO
ydを含むフラスコ2本に夫々7セトン乾燥菌体1゜■
加え、更に2本のうちの1本にはML −236BNa
 塩5〜を、他の1本にはモナコリンK Na iX 
519を夫々加えて30℃で20時間軽く振と5した。
50mM phosphate potassium 7- (pH 8,0) jO
7 setsone dried bacterial cells 1° in each of 2 flasks containing yd.
In addition, one of the two bottles contains ML-236BNa.
5~ of salt, and Monacolin K Na iX for the other one.
519 was added to the mixture, and the mixture was gently shaken at 30° C. for 20 hours.

以下、実施例3と同じ操作を行ないML −236A4
2キ及モナフリンJ 3.6 Nを得た。
Hereinafter, the same operation as in Example 3 was performed to obtain ML-236A4.
2 kg and 3.6 N of Monafrin J were obtained.

実施例5 実施例4で得られた7セトン乾燥菌体19を0.2Mリ
ン酸カリバッフ7− (pH8,0) 40m1lfC
げんだくして5分間超音波熟理を行ない、その後4℃で
時々攪拌しながら20時間抽出した。ろ過により得られ
た透明な抽出液5ゴと50 mMリン酸カリパンファー
(pH8,0) 5 mlを含む試験管2本を用意し、
一方にML −236B Nm塩を、他方にモナコリン
K Na塩を夫々5ダ加えて30℃で5時間静置した。
Example 5 The 7setone dried bacterial cells 19 obtained in Example 4 were added to 0.2M phosphate potassium buff 7- (pH 8,0) 40ml 1lfC
The mixture was stirred and subjected to ultrasonic ripening for 5 minutes, and then extracted at 4°C for 20 hours with occasional stirring. Prepare two test tubes containing the transparent extract obtained by filtration and 5 ml of 50 mM potassium phosphate (pH 8,0).
ML-236B Nm salt was added to one side, and monacolin K Na salt was added to the other side for 5 hours, and the mixture was allowed to stand at 30°C for 5 hours.

その後反応液にトリフルオル酢酸を加えてpH3とし、
以下実施例3と同様に抽出操作。
After that, trifluoroacetic acid was added to the reaction solution to adjust the pH to 3,
The extraction operation was then carried out in the same manner as in Example 3.

高速液体りpマドグラフィーにがけML −236A4
、五〜及びモナコリンJ 3.8■を夫々得た。
High-speed liquid printer ML-236A4
, 5 ~ and Monacolin J 3.8■ were obtained, respectively.

出願人 遠 藤 章Applicant: Akira Endo

Claims (1)

【特許請求の範囲】 1、゛ モルチンラ属、エメリセラj1.ジヘテpスポ
ラ属、7ミコラ属、ジコトモミセス属、ネオコスモスポ
ラ属、キシρゴ/属、トルpiセス属及びチェラビア属
に属するかびを用いてML−236B及びモナコリンK
から夫々ML −236A及びモナフリンJを製造する
ことを特徴とするML −236A及びモナコリンJの
製造法。 2 かびがモルチレラ・イサベリナ、エメリセラ拳つン
グイス、ジヘテpスボラリラミドスポリ7.フミコラ・
フスコアトラ、ジコトモミセス・センユピ、ネオコスモ
スポラ・アフリカナ、キシルボン・スフエルスポラ、ト
ルcxミセス・ラグナ、チェラビア・ヒメテイ又はこれ
らの変種又は変異株である特許請求の範囲第1項ハ 記載の生理活性物質ML −236−B−及びモナコリ
ンJの製造法。
[Scope of Claims] 1. ``Mortinula sp., Emericella j1. ML-236B and Monacolin K were obtained using molds belonging to the genus Dihetepspora, 7 Mycolas, Dichotomomyces, Neocosmospora, Xygo/, Torpices, and Cherabia.
A method for producing ML-236A and monacolin J, comprising producing ML-236A and monacolin J, respectively. 2. Molds Mortillera Isabelina, Emerisella fistulae, Jihete p sborarilamidospori 7. Fumicola・
The physiologically active substance ML-236 according to Claim 1 C, which is Fuscoatla, Dichotomyces senupi, Neocosmospora africana, Xylvon sfuerspora, Torcx Myces laguna, Chelavia hymetei, or a variant or mutant strain thereof -B- and a method for producing Monacolin J.
JP3113784A 1984-02-21 1984-02-21 Preparation of physiologically active substance ml-236a and monacolin j Pending JPS60176595A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3113784A JPS60176595A (en) 1984-02-21 1984-02-21 Preparation of physiologically active substance ml-236a and monacolin j

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3113784A JPS60176595A (en) 1984-02-21 1984-02-21 Preparation of physiologically active substance ml-236a and monacolin j

Publications (1)

Publication Number Publication Date
JPS60176595A true JPS60176595A (en) 1985-09-10

Family

ID=12323047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3113784A Pending JPS60176595A (en) 1984-02-21 1984-02-21 Preparation of physiologically active substance ml-236a and monacolin j

Country Status (1)

Country Link
JP (1) JPS60176595A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486153A2 (en) * 1990-10-15 1992-05-20 Merck & Co. Inc. Enzymatic hydrolysis of lovastatin acid using an enzyme derived from Clonostachys compactiuscula
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
WO1994026920A1 (en) * 1993-05-11 1994-11-24 Merck & Co., Inc. PROCESS FOR SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS
US5620876A (en) * 1992-04-29 1997-04-15 E. R. Squibb & Sons, Inc. Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
WO2010043748A1 (en) 2008-10-15 2010-04-22 Neuron Biopharma, S.A. Biosynthesis of derivatives of monacolin j

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486153A2 (en) * 1990-10-15 1992-05-20 Merck & Co. Inc. Enzymatic hydrolysis of lovastatin acid using an enzyme derived from Clonostachys compactiuscula
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
CN1053219C (en) * 1992-02-07 2000-06-07 麦克公司 Biochemical purification of simvastatin
US5620876A (en) * 1992-04-29 1997-04-15 E. R. Squibb & Sons, Inc. Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
WO1994026920A1 (en) * 1993-05-11 1994-11-24 Merck & Co., Inc. PROCESS FOR SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS
US5420024A (en) * 1993-05-11 1995-05-30 Merck & Co., Inc. Process for synthesis of acylated HMG-CoA reductase inhibitors from a lactone diol precursor using Candida cylindracea
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
WO2010043748A1 (en) 2008-10-15 2010-04-22 Neuron Biopharma, S.A. Biosynthesis of derivatives of monacolin j

Similar Documents

Publication Publication Date Title
EP0204009B1 (en) Process for producing diol and furan and microorganism capable of same
KR840002294B1 (en) Process for preparing deacetyl-cephalosporin-c
JPS60176595A (en) Preparation of physiologically active substance ml-236a and monacolin j
US4798799A (en) Process for producing diol and furan and microorganism capable of same
JPH10130269A (en) Carboline derivative
NL8204904A (en) DIHYDRO- AND TETRAHYDROMONACOLIN L, METAL SALTS AND ALKYL ESTERS, AND METHOD FOR PREPARING THE SAME.
JP3178089B2 (en) Method for producing optically active mandelic acid
US3975235A (en) Process for the production of cephamycin type antibiotic substances
JPH06256278A (en) Optically active alpha-carbamoylalkanoic acid derivative and its production
KR100260542B1 (en) Method for producing optically active norborneol
JP2954700B2 (en) Compound MS-347
JPH0355471B2 (en)
JP3872135B2 (en) Process for producing optically active γ-butyrolactone derivative
US4992570A (en) UCN-1028A and UCN-1028C and process for the production thereof
JP3452378B2 (en) Production method of halogenated compounds
JPH0984591A (en) Carotenoid sulfate and its production
JPS6261587A (en) Production of optically active (r)-hydroxymandelic acid ester intermediate
JP2624296B2 (en) Method for producing γ-halo-β-hydroxybutyrate
JPS6012993A (en) Production of optically active carboxylic acid
EP1096019A1 (en) Process for preparing optically active 4-halogeno-1, 3-butanediol and its derivatives by microorganism
SU1497185A1 (en) Method of producing prostaglandins
JPH11269175A (en) New ultraviolet-absorbing substance produced by marine bacteria and its production
JPS58138390A (en) Biological method of producing rifamicin derivative
JP3327982B2 (en) New antibiotic MI481-42F4-A related substance
JP2844854B2 (en) FR901308 substance and method for producing the same